CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Fermer

Use of miR-199a-5p, targets and/or inhibitors thereof for the diagnosis, prognosis and treatment of fibroproliferative disorders

Référence

04793-01

Statut des brevets

French priority patent application n° FR20120051089 filed on February 06, 2012
WO2013118066
EP 2812449
US 14/376569
JP IB2013050989-392
CA2862275

Inventeurs

Bernard MARI
Nicolas POTTIER
Brice MARCET
Pascal BARBRY

Statut commercial

Exclusive or non-exclusive license

Laboratoire

Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275, Nice-Sophia Antipolis, France.
Laboratory EA4483 Lille, France

Description

CONTEXT

Tissue fibrosis, defined as the excessive persistent formation of non functional scar tissue in response to a chronic tissue lesion, is a worldwide leading cause of morbidity and mortality associated with organ failure in various chronic diseases such as those affecting the pulmonary interstitium. Fibroproliferative disorders are a major public health problem. Indeed, in the USA alone, 45% of deaths are attributed to fibroproliferative disorders.
In particular, Idiopathic pulmonary fibrosis (IPF), the most common and lethal interstitial lung disease of unknown etiology, is a highly morbid progressive disease with an average survival rate of 3 to 5 years post-diagnosis.

This devastating disease affects about 360.000 patients in the EU/US and causes a substantial socio-economic burden. IPF is a disease associated with aging and as such its incidence is increasing in the whole world. Lung fibrosis is an irreversible phenomenon and, currently, no effective treatment has been shown to reverse this process.

TECHNICAL DESCRIPTION

A new strategy based on miRNA has been developped by the 2 teams (Bernard Mari and Nicolas Pottier) associated with the technology. It proposes the use of the miRNA expression profile, particularly miR-199a-5p and the target genes regulated thereby for the diagnosis, prognosis and more particularly the use of miR-199a-5p inhibitors for treating fibroproliferative disorders (pulmonary, hepatic and renal fibrosis), especially IPF.
Interestingly, the inventors established miR-199a-5p as a critical effector of the fibrogenic response to tissue injury and demonstrated its role in mediating TGF-β1-induced lung fibroblast activation by targeting caveolin-1 (CAV1), a structural component of caveolae, known as a potent inhibitor of pulmonary fibrosis.
Two therapeutic strategies are proposed using LNA-based oligonucleotides either designed against miR-199a-5p (anti-miR-LNA) or interfering with CAV1 3’UTR mRNA (CAV1 Target Site Blocker, TSB).

BENEFITS

Mir-199a is a critical effector of the TGF-β pathway, a major pathway involved in the activation of fibroblasts into myofibroblasts.
The proposed inhibitors are of a small size, and TSB allow more specificity of action on the target CAV1.

INDUSTRIAL APPLICATIONS

The technology address the field of fibroproliferative disorders, more particularly it may be used for the diagnosis-prognosis and the treatment of the IPF.
The market of the IPF is estimated to reach 4.6 billion dollars in the USA and Europe in 2020.

DEVELOPMENT STAGE

– Optimization design of the inhibitors for in vivo administration (partnership with biotech);
– In vitro tests and selection of the best TSB;
– In vivo  pre-clinical evaluation of miR-199a-5p inhibitors are ongoing in a mouse model of pulmonary fibrosis and show promising preliminary results;
– Upcoming steps:
In vivo tests with CAV1-TSB;
In vivo activity-survival.

PUBLICATIONS

miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1.
Lino Cardenas CL, Henaoui IS, Courcot E, Roderburg C, Cauffiez C, Aubert S, Copin MC, Wallaert B, Glowacki F, Dewaeles E, Milosevic J, Maurizio J, Tedrow J, Marcet B, Lo-Guidice JM, Kaminski N, Barbry P, Luedde T, Perrais M, Mari B, Pottier N.
PLoS Genet. 2013; 9(2):e1003291.

Pottier, N., Cauffiez, C., Perrais, M., Barbry, P. and Mari, B (2014). FibromiRs: translating molecular discoveries into new anti-fibrotic drugs. Trends Pharmacol Sci 35:119-26.

miR-199a-5p in idiopathic pulmonary fibrosis.
Henaoui IS, Cauffiez C, Aubert S, Buscot M, Dewaeles E, Copin MC, Marquette CH, Barbry P, Perrais M, Pottier N, Mari B.
Med Sci (Paris). 2013 May; 29(5):461-3

For further information, please contact us (Ref 04793-01)

Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • This field is for validation purposes and should be left unchanged.
Fermer

Les brevets les plus récents